Antimycotic activity of BAY N 7133 in animal experiments.
The triazole derivative BAY N 7133 has been tested for its antimycotic efficacy on oral administration in vivo and compared with ketoconazole in mice infected with Candida albicans, Aspergillus fumigatus and Cryptococcus neoformans and in guinea pig trichophytosis. On starting administration at the same time as infection and using daily doses between 25 and 100 mg/kg, the agent protected the mice in all experimental models, even mouse aspergillosis for which ketoconazole was not adequately effective. BAY N 7133 was also effective for mouse candidosis by parenteral administration and was effective for guinea pig trichophytosis on topical application.
D000284:Administration, Oral; D000287:Administration, Topical; D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy; D002177:Candidiasis / Q000188:drug therapy; D003453:Cryptococcosis / Q000188:drug therapy; D005260:Female; D005437:Flucytosine / Q000627:therapeutic use; D006168:Guinea Pigs; D006197:Hair / Q000032:analysis; D007263:Infusions, Parenteral; D007654:Ketoconazole / Q000627:therapeutic use; D008297:Male; D051379:Mice; D009181:Mycoses / Q000188:drug therapy*; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use*
D000935:Antifungal Agents; D014230:Triazoles; D000666:Amphotericin B; C037494:vibunazole; D005437:Flucytosine; D007654:Ketoconazole